[Form 3] Ocuphire Pharma, Inc. Common Stock Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Robert E. Gagnon, listed at C/O Opus Genetics, Inc., filed an Initial Form 3 reporting his relationship to the issuer as a director and Chief Financial Officer. The event date is 09/02/2025. The filing states no securities are beneficially owned and includes Exhibit 24 (Power of Attorney). The form was signed by Amy Rabourn by power of attorney on 09/11/2025.

Insights

Corporate Governance Expert

TL;DR: Routine initial Section 16 filing showing officer/director with no reportable holdings.

The Form 3 documents an officer and director relationship without any beneficial ownership, which is uncommon but straightforward: it may reflect timing of appointment before receipt of equity awards or ownership, or a deliberate absence of holdings. The inclusion of Exhibit 24 indicates an executed power of attorney used to file, and the POA signature date is provided. No material transaction or ownership position is disclosed, so there is no immediate governance red flag in this filing alone.

Securities Compliance Analyst

TL;DR: Compliance filing is complete and routine; no reportable securities eliminate immediate Section 16 reporting obligations beyond this initial record.

The report satisfies Section 16 initial reporting requirements by identifying the reporting person, role, issuer, and event date. The explicit statement that "No securities are beneficially owned" removes the need to list holdings or derivative positions. The filing is executed via POA, which is acceptable practice; the document does not disclose subsequent transactions or potential reporting triggers.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gagnon Robert E.

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/02/2025

3. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Amy Rabourn, by Power of Attorney	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for Opus Genetics, Inc. (IRD)?

Robert E. Gagnon filed the Form 3, listed as a director and Chief Financial Officer.

Does the Form 3 report any securities beneficially owned?

No. The filing explicitly states that no securities are beneficially owned by the reporting person.

What is the event date reported on the Form 3?

09/02/2025 is listed as the date of the event requiring the statement.

Was the Form 3 signed directly by the reporting person?

No. The form was signed by Amy Rabourn by Power of Attorney on 09/11/2025.

Does the filing include any exhibits?

Yes. The filing lists Exhibit 24, which is a Power of Attorney.